Evidence map›Paper›PMID 27643717›Full record

ReviewAmerican journal of clinical oncology2016

ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.

Sughosh Dhakal, Ranjana Advani, Leslie K Ballas, Bouthaina S Dabaja, Christopher R Flowers, Chul S Ha, Bradford S Hoppe, Nancy P Mendenhall, Monika L Metzger, John P Plastaras and 8 more

Abstract readComparative StudyReview
In one paragraph

Review in American journal of clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sughosh Dhakal*University of Rochester Medical Center, Rochester †††Memorial Sloan Kettering Cancer Center, American Society of Clinical Oncology, New York, NY †Stanford Cancer Center, American Society of Clinical Oncology, Stanford ‡University of Southern California Keck School of Medicine, Los Angeles, CA §University of Texas MD Anderson Cancer Center, Houston ¶University of Texas Health Science Center at San Antonio, San Antonio, TX ∥Emory University, American Society of Clinical Oncology, Atlanta, GA #University of Florida Proton Therapy Institute, Jacksonville **University of Florida, Gainesville, FL ††St. Jude Children's Research Hospital, American Society of Clinical Oncology, Memphis, TN ‡‡University of Pennsylvania Health System, Philadelphia, PA §§Yale University School of Medicine, New Haven, CT ∥∥Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN ¶¶The University of Chicago, American Society of Hematology, Chicago, IL ##Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD ***Massachusetts General Hospital, Boston, MA.
Ranjana Advani
Leslie K Ballas
Bouthaina S Dabaja
Christopher R Flowers
Chul S Ha
Bradford S Hoppe
Nancy P Mendenhall
Monika L Metzger
John P Plastaras
Kenneth B Roberts
Ronald Shapiro
Sonali M Smith
Stephanie A Terezakis
Karen M Winkfield
Anas Younes
Louis S Constine
Expert Panel on Radiation Oncology–Lymphoma

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

This topic addresses the treatment of newly diagnosed patients with favorable prognosis stage I and II Hodgkin lymphoma. In most cases, combined modality therapy (chemotherapy followed by involved site radiation therapy) constitutes the current standard of care. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the appropriate use of combined modality therapy for favorable prognosis stage I and II Hodgkin lymphoma. Increasing information about the late effects of treatment has led to attempts to decrease toxicity by using less chemotherapy (decreased duration and/or intensity or different agents) and less radiation therapy (reduced volume and/or dose) while maintaining excellent efficacy.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyDisease-Free SurvivalDose-Response Relationship, DrugFemaleHodgkin DiseaseHumansMaleNeoplasm InvasivenessNeoplasm StagingOutcome Assessment, Health CarePractice Guidelines as TopicRadiotherapy DosageRandomized Controlled Trials as TopicRisk Assessment

Identifiers

PMID27643717
PMCPMC7433865

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.